^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

SGN-CD70A

i
Other names: SGN-CD70A, SGN 70A
Company:
Pfizer
Drug class:
DNA replication inhibitor, CD70-targeted antibody-drug conjugate
3years
Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models. (PubMed, Blood Adv)
Most importantly, multiple-dosing of SGN-CD70A induced complete eradication of established tumors in PDXs measured by cfDNA. Our results demonstrated marked anti-tumor activity of SGN-CD70A in CTCL PDXs, providing compelling support for its clinical investigation.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • CD70 (CD70 Molecule)
|
CD70 expression
|
SGN-CD70A
almost4years
[VIRTUAL] A CD70 antibody-drug conjugate is highly active and induces long term remission in patient-derived xenograft mouse models of cutaneous T cell lymphoma (AACR 2021)
One week after tumor inoculation, mice were treated intraperitoneally with single-dosing of PBS, 100 μg/kg (SGN70A100) or 300 μg/kg (SGN70A300) of SGN-CD70A. Using CTCL PDX models, SGN-CD70A has marked anti-tumor activity, leading to long-term survival of treated mice. Our results provide a rationale for clinical investigation of SGN-CD70A in patients with TCL.
Preclinical
|
CD70 (CD70 Molecule)
|
CD70 expression
|
SGN-CD70A • vorsetuzumab (SGN70)
almost5years
A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma. (PubMed, Invest New Drugs)
SGN-CD70A exposures were approximately dose proportional, with a mean terminal half-life of 3 to 5 days. Conclusions While modest single-agent activity was observed in heavily pretreated NHL patients, the applicability of SGN-CD70A is limited by the frequency and severity of thrombocytopenia, despite the long-term response with limited drug exposure.
Clinical • P1 data • Journal
|
CD70 (CD70 Molecule)
|
SGN-CD70A